Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Patients that are able to receive CAR T-cell therapy have a potential for cure, however, many will not be qualified to receive therapy due to relapse. Bridging therapy is therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy. Golcadomide may help block the formation, growth or spread of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving golcadomide and rituximab as bridging therapy before CAR T-cell therapy may kill more tumor cells and may improve the chance of proceeding to CAR T-cell therapy in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzona diagnoza agresywnego chłoniaka B, który powrócił lub nie odpowiada na leczenie, po maksymalnie dwóch wcześniejszych terapiach
- •Chłoniak musi być widoczny w badaniu PET-CT (co najmniej jedna zmiana o rozmiarze powyżej 1,5 cm)
- •Pacjent kwalifikuje się do terapii CAR-T według oceny lekarza prowadzącego
- •Ogólny stan zdrowia pacjenta (skala ECOG) w zakresie 0, 1 lub 2
- •Poziom hemoglobiny powyżej 7.0 g/dL
- •Odpowiednia liczba białych krwinek (neutrofile ANC ≥ 1000/mcL)
- •Odpowiednia liczba płytek krwi (powyżej 75 000/mcL)
✗ Disqualifies
- •Pacjenci z niektórymi typami chłoniaków, np. transformowanym chłoniakiem Richtera.
- •Chłoniak nie jest wystarczająco duży, by być widocznym w badaniu PET-CT lub jest widoczny tylko w badaniu palpacyjnym.
- •Chłoniak w obszarze, który był wcześniej naświetlany (radioterapia).
- •Wiek poniżej 18 lat.
- •Stan zdrowia pacjenta nie pozwala na podjęcie terapii CAR-T.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Mayo Clinic in Arizona
Scottsdale, United States
Mayo Clinic in Florida
Jacksonville, United States
Mayo Clinic Health System in Albert Lea
Albert Lea, United States
Mayo Clinic Health Systems-Mankato
Mankato, United States
Mayo Clinic in Rochester
Rochester, United States
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, United States
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, United States
Trial contact
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.